Literature DB >> 15262183

Screening for functional sequence variations and mutations in ABCA1.

Mario C O Probst1, Harald Thumann, Charalampos Aslanidis, Thomas Langmann, Christa Buechler, Wolfgang Patsch, Francisco E Baralle, Geesje M Dallinga-Thie, Jürgen Geisel, Christiane Keller, Valentine C Menys, Gerd Schmitz.   

Abstract

Mutations in the ATP-binding cassette 1 transporter gene (ABCA1) are responsible for the genetic HDL-deficiency syndromes, which are characterized by severely diminished plasma HDL-C levels and a predisposition to cardiovascular disease and splenomegaly. The ABCA1 gene contains 50 exons and codes for a 2261-amino acid long membrane protein that facilitates phospholipid and cholesterol transport. Several mutations have been identified so far as responsible either for Tangier disease or for reduced HDL levels. We have selectively looked for additional polymorphisms in functionally relevant regions of the gene in cohorts constituted of individuals with altered HDL levels as well as healthy blood donors and octogenarians, and screened for mutations in the complete coding region of selected individuals with extremely aberrant HDL levels. In the promoter region, which is important for regulation of gene expression, we have identified several polymorphisms including one VNTR polymorphism, located at a putative ZNF202 binding site, which displayed different binding of ZNF202 in an electromobility shift assay. Three novel SNPs were discovered in the promoter region (G1047C, C1152T and C1440T). The prevalence of exchange G1047C (G-395C) was found significantly increased in probands with low HDL compared to probands with high HDL. Exchanges C1152T (C-290T) and C1440T (C-7T) were significantly more frequent in the cohort with low HDL compared to healthy blood donors and octogenarians. In the C-terminal part of ABCA1, known to interact with other proteins, two novel sequence variations (F2163S and V2244I) have been found in one phenotype related to cardiovascular disease, but none in the aforementioned cohorts. In one individual with extremely high HDL levels, the V771M polymorphism was found in a homozygous state. In patients with HDL deficiency, three novel mutations have been identified (W590L, W840R and R1068C). To facilitate further research in ABCA1 sequence variations and expand our understanding of their effects, we are introducing a webpage archive (http://www.abca1-mutants.all.at) containing all sequence variations reported in ABCA1 so far. This webpage provides a more recent and detailed summary of sequence variations and mutations in ABCA1 than existing databases and should also be of interest for molecular diagnosis of ABCA1-related HDL deficiency. Copyright 2004 Elsevier Ireland Ltd

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15262183     DOI: 10.1016/j.atherosclerosis.2004.02.019

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  11 in total

1.  Significance of Cholesterol-Binding Motifs in ABCA1, ABCG1, and SR-B1 Structure.

Authors:  Alexander D Dergunov; Eugeny V Savushkin; Liudmila V Dergunova; Dmitry Y Litvinov
Journal:  J Membr Biol       Date:  2018-12-06       Impact factor: 1.843

Review 2.  Genetic causes of high and low serum HDL-cholesterol.

Authors:  Daphna Weissglas-Volkov; Päivi Pajukanta
Journal:  J Lipid Res       Date:  2010-04-26       Impact factor: 5.922

3.  Targeted next-generation sequencing to diagnose disorders of HDL cholesterol.

Authors:  Singh N Sadananda; Jia Nee Foo; Meng Tiak Toh; Lubomira Cermakova; Laia Trigueros-Motos; Teddy Chan; Herty Liany; Jennifer A Collins; Sima Gerami; Roshni R Singaraja; Michael R Hayden; Gordon A Francis; Jiri Frohlich; Chiea Chuen Khor; Liam R Brunham
Journal:  J Lipid Res       Date:  2015-08-08       Impact factor: 5.922

4.  Hypermethylation at loci sensitive to the prenatal environment is associated with increased incidence of myocardial infarction.

Authors:  Rudolf P Talens; J W Jukema; S Trompet; D Kremer; R G J Westendorp; L H Lumey; N Sattar; Hein Putter; P E Slagboom; B T Heijmans
Journal:  Int J Epidemiol       Date:  2011-11-17       Impact factor: 7.196

Review 5.  ABCA1, from pathology to membrane function.

Authors:  Ana Zarubica; Doriane Trompier; Giovanna Chimini
Journal:  Pflugers Arch       Date:  2006-07-21       Impact factor: 3.657

6.  Epigenetic variation during the adult lifespan: cross-sectional and longitudinal data on monozygotic twin pairs.

Authors:  Rudolf P Talens; Kaare Christensen; Hein Putter; Gonneke Willemsen; Lene Christiansen; Dennis Kremer; H Eka D Suchiman; P Eline Slagboom; Dorret I Boomsma; Bastiaan T Heijmans
Journal:  Aging Cell       Date:  2012-06-04       Impact factor: 9.304

7.  Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms.

Authors:  Suzanne E Wahrle; Aarti R Shah; Anne M Fagan; Scott Smemo; John S K Kauwe; Andrew Grupe; Anthony Hinrichs; Kevin Mayo; Hong Jiang; Leon J Thal; Alison M Goate; David M Holtzman
Journal:  Mol Neurodegener       Date:  2007-04-12       Impact factor: 14.195

Review 8.  Isolated low high density lipoprotein-cholesterol (HDL-C): implications of global risk reduction. Case report and systematic scientific review.

Authors:  Melvin R Hayden; Suresh C Tyagi
Journal:  Cardiovasc Diabetol       Date:  2005-01-04       Impact factor: 9.951

9.  A Comprehensive In Silico Analysis of the Functional and Structural Impact of Nonsynonymous SNPs in the ABCA1 Transporter Gene.

Authors:  Francisco R Marín-Martín; Cristina Soler-Rivas; Roberto Martín-Hernández; Arantxa Rodriguez-Casado
Journal:  Cholesterol       Date:  2014-08-19

10.  Histone Methyltransferase Enhancer of Zeste Homolog 2-Mediated ABCA1 Promoter DNA Methylation Contributes to the Progression of Atherosclerosis.

Authors:  Yun-Cheng Lv; Yan-Yan Tang; Ping Zhang; Wei Wan; Feng Yao; Ping-Ping He; Wei Xie; Zhong-Cheng Mo; Jin-Feng Shi; Jian-Feng Wu; Juan Peng; Dan Liu; Francisco S Cayabyab; Xi-Long Zheng; Xiang-Yang Tang; Xin-Ping Ouyang; Chao-Ke Tang
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.